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Abstract 
Background: Postoperative complications after oesophagectomy are thought to be associated with 
reduced fitness. This observational study explored the associations between aerobic fitness, as 
determined objectively by preoperative cardiopulmonary exercise testing (CPEX), and 30-day 
morbidity after oesophagectomy. Methods: We retrospectively identified 254 consecutive patients 
who underwent oesophagectomy at a single academic teaching hospital between September 2011 
and March 2017. Postoperative complication data were measured using the Esophageal Complications 
Consensus Group definitions and graded using the Clavien-Dindo classification system of severity 
(blinded to CPEX values). Associations between preoperative CPEX variables and postoperative 
outcomes were estimated using logistic regression. Results: Two hundred and six patients (77% male) 
were included in the analyses, with a mean age of 67 years (SD 9). The mean values for VO2peak and AT 
were 21.1ml/kg/min (SD 4.5) and 12.4ml/kg/min (SD 2.8), respectively. The vast majority of patients 
(98.5%) had malignant disease; predominantly adenocarcinoma (84.5%), for which most received 
neoadjuvant chemotherapy (79%) and underwent minimally invasive Ivor Lewis oesophagectomy 
(53%). Complications at postoperative day 30 occurred in 111 patients (54%), the majority of which 
were cardiopulmonary (72%). No associations were found between preoperative CPEX variables and 
morbidity for either VO2peak (OR 1.00, 95% CI 0.94-1.07) or AT (OR 0.98, 95% CI 0.89-1.09). 
Conclusions: Preoperative CPEX variables were not associated with 30-day complications following 
oesophagectomy. The findings do not support the use of CPEX as an isolated preoperative screening 
tool to predict short-term morbidity after oesophagectomy. This modestly sized observational work 
highlights the need for larger studies examining associations between preoperative CPEX and 
outcomes after oesophagectomy to look for consistency in our findings.  
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Introduction 
Oesophageal resection and reconstruction (oesophagectomy) is the only consistent treatment 
modality that offers a potential cure for oesophageal cancer,1 but carries a high risk of postoperative 
complications. UK national audit figures report that 33% of patients suffer a complication after 
oesophagectomy, most of which (74%) affect the cardiopulmonary system (52% respiratory and 22% 
cardiac).2 Increased preoperative physical fitness may reduce the number of postoperative 
complications. Exercise results in a greater cardiac output, improved respiratory muscle strength and 
skeletal muscle adaptations (improved transport and metabolism of oxygen to produce adenosine 
triphosphate (ATP)).3  These adaptations may attenuate the physiological insults of oesophagectomy 
which include; disruption of normal lung mechanics through incisional pain and diaphragmatic 
dysfunction;4 blood loss and sympathetic activation, resulting in splanchnic vasoconstriction - which 
jeopardises any newly formed gastroesophageal anastomosis; and a surgical stress response, resulting 
in catabolism of skeletal muscle protein 5 and increased oxygen demand and consumption.6 Accurate 
measurement of preoperative cardiopulmonary fitness may identify patients at higher risk of 
complications due to low cardiopulmonary reserves. This could allow better perioperative 
management to improve outcomes, including modification of fitness with an exercise programme.   
CPEX is an objective, quantitative and composite measure of a person’s overall aerobic fitness. Two 
specific CPEX variables; VO2peak (the maximal oxygen consumed at the peak of exercise) and VO2 at 
estimated anaerobic threshold (AT) have shown promise in observational studies to predict both 
morbidity and mortality.7-13 In a study of 187 elderly patients undergoing major abdominal surgery, a 
preoperative AT cut-off of <11ml/kg/min had a sensitivity of 91% and specificity of 74% for predicting 
mortality.7 In a multi-centre study of 346 lung cancer patients undergoing resection via thoracotomy, 
a VO2max cut-off of <16ml/kg/min predicted patients more likely to suffer a complication (p=0.0001).14 
To the best of our knowledge, there have only been three relatively small observational studies of 
CPEX testing prior to oesophagectomy (n=78,12 n=91,10 n=103 11). And whilst two of these studies 
reported an inverse association between VO2peak and cardiopulmonary complications 10 12, one did 
not.11  Similar conflicting findings were found for AT, with only one study reporting a significant 
association.11  Differences in the measurement of outcomes by non-blinded assessors is likely to have 
introduced methodological error, which may explain the variation in findings. As such, the utility of 
CPEX prior to oesophagectomy is uncertain. Our study aimed to clarify the associations between CPEX 
variables, specifically VO2peak and AT, and 30-day morbidity after oesophagectomy through the use of 
a larger sample size and measurement of outcomes using a standardised assessment tool, blinded to 
CPEX data. 
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Methods 
Study setting and patient population 
This hospital-based cohort study was conducted in the Department of Upper Gastrointestinal (UGI) 
Surgery at the Norfolk and Norwich University Hospitals (NNUH) Foundation Trust, Norwich, United 
Kingdom. The NNUH is a 1,000 bed teaching hospital, which provides care to a population of 
approximately 825,000 residents in Norfolk and adjacent counties. Approximately 45 
oesophagectomies are performed at this unit each year. We retrospectively identified all patients who 
underwent an oesophagectomy at our institution between 1st September 2011 (the date of the first 
CPEX test prior to oesophagectomy) and 9th March 2017 (the latest date that would allow 30-day 
outcome assessment). At our centre, CPEX testing is used in all patients undergoing oesophagectomy 
after the decision to operate has been made. None of the authors had any input in the initiation of 
CPEX testing at our centre. Patients were excluded if they had emergency or palliative surgery, a 
pharyngolaryngo-oesophagectomy, oesophagectomy and gastrectomy or did not undergo CPEX 
testing. The study protocol was registered on ClinicalTrials.Gov (NCT03216694) and formal ethical 
approval was granted by the North West - Liverpool Central Research Ethics Committee after 
proportionate review (17/NW/0435, IRAS Project ID: 222793). 
 
Cardiopulmonary exercise testing 
CPEX testing was undertaken in a respiratory laboratory at the NNUH on an electromagnetically 
braked cycle ergometer (Ergoselect 200, Ergoline GmbH, Lindenstrasse 5, D-72475, Bitz, Germany). 
Testing consisted of a 3 minute rest period, 3 minutes of free pedalling and an incremental ramped 
phase, usually lasting 8-12 minutes, until volitional termination. Gas exchange was measured using a 
metabolic cart (Jaeger Oxycon Pro, CareFusion, Germany 234 GmbH, Leibnizstrasse 7, 97204, 
Hoechberg). AT was estimated using the V-slope method (change in the linear relationships between 
VCO2 and VO2) and VO2peak was averaged over 30 seconds during peak exercise. The median time 
between CPEX testing and surgery was 11 days (interquartile range (IQR) = 7-19 days). None of the 
patients were deemed unfit for CPEX testing. At surgery, patients underwent either: McKeown, 
partially laparoscopic assisted (hybrid), or fully laparoscopic (minimally invasive) Ivor Lewis 
oesophagectomy. All patients were admitted to a high dependency unit (HDU) for the first night 
following surgery. Step down to ward care was decided by the HDU consultant.  
 
Variable measurement 
The following patient data were obtained by review of medical notes: age, gender, smoking status 
(never, former, current), body mass index (BMI), comorbidities (classified according to the Charlson 
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comorbidity index), TNM staging, chemotherapy regimen, type of surgery received and histology. To 
reduce the risk of selective reporting bias, CPEX variables of interest (VO2peak and AT) were decided a 
priori under a registered protocol.  CPEX data was obtained by an investigator (G.H) who was not 
involved in the collection of outcome data.  Similarly, the outcome assessor (S.L) was blinded to 
preoperative CPEX values and not involved in the collection of CPEX data. In order to reduce 
measurement error, short-term morbidity was measured by hand review of the medical notes, in strict 
accordance with Esophageal Complications Consensus Group (ECCG) definitions.15 Each complication 
was then graded in accordance with the Clavien-Dindo classification.16 In brief; grade 1 complications 
do not require pharmacological intervention above usual postoperative care, while grade 2 
complications do. Grade 3a complications require a surgical intervention without general anaesthesia; 
grade 3b require a return to theatre; and grade 4 require organ support on ITU. The primary aim was 
to establish the association between the preoperative CPEX variables VO2peak and AT and 30-day 
morbidity (all cause, cardiopulmonary and non-cardiopulmonary) as defined by ECCG of Clavien-Dindo 
grade 2 or above (complications of significant clinical importance). Secondary aims were to measure 
associations between CPEX variables and specific common complications and 30 and 90 day mortality. 
 
Statistical methods 
Continuous variables were reported as mean and standard deviation or median and IQR depending 
on the distributions. Categorical variables were presented as frequency (%). P-values were obtained 
using Student-t tests, X2 or Fisher’s exact tests. For the comparative analyses in table 2, statistical 
significance was taken at p=0.0008 after Bonferroni correction for multiple statistical testing. A 
Multivariable logistic regression model was constructed based on variables with both a plausible and 
univariable association with outcome, with CPEX values treated as a continuous variable. All statistical 
analyses were done using Stata (version 12.1, StataCorp, 4905 Lakeway Drive, College Station, Texas 
77845, USA).  
 
Results 
Between 1st September 2011 and 9th March 2017 (5 ½ years) 254 patients underwent an 
oesophagectomy at the NNUH. Of these patients, 48 were excluded: 40 did not undergo CPEX testing, 
4 had emergency surgery and 4 had extended and palliative oesophagectomies.  Therefore, 206 
patients (77% male) were included in the analyses, with a mean age of 67 years (SD 9) at the time of 
surgery (table 1). In the whole cohort, the mean values for VO2peak and AT were 21.1ml/kg/min (SD 
4.5) and 12.4 ml/kg/min (SD 2.8), respectively. The vast majority of patients (98.5%) had malignant 
disease; predominantly adenocarcinoma (84.5%), for which most received neoadjuvant 
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chemotherapy (79%) and underwent minimally invasive Ivor Lewis oesophagectomy (53%). Thirty day 
complications occurred in 111 patients (54%), the majority of which were cardiopulmonary (72%).  The 
40 patients who underwent oesophagectomy without preoperative CPEX were similar in their 
demographics and outcomes compared to those with CPEX data (supplementary table 1). The reasons 
for absence of CPEX testing was not documented in the notes, and were most were likely due to 
logistical issues associated with arranging these tests. The assumption was that these data were 
missing completely at random (MCAR). There was no documented evidence that any of these patients 
were selected not to undergo CPEX testing.  The median length of hospital stay was 9 days (IQR 7-14 
days). No deaths occurred at postoperative day 30, but 7 patients died at day 90 (3.4%); 2 due to 
malignant progression, 2 due to cardiopulmonary complications (VO2peak 16.2 and 21.1ml/kg/min and 
AT 10.1 and 9.5ml/kg/min), and 3 due to non-cardiopulmonary complications (VO2peak 14.5, 15.6 and 
20.8ml/kg/min and AT 8.7, 8.8 and 10.6ml/kg/min).  
Table 2 shows patients grouped by whether or not they suffered; any complication, a 
cardiopulmonary, or a non-cardiopulmonary complication. These groups differed in ASA grade I, type 
of operation, duration of surgery and length of stay. However, only length of stay met statistical 
significance after adjustment for multiple statistical testing (Bonferroni correction, p=0.0008). Neither 
VO2peak or AT were associated with complications of any type or severity (table 3). We further grouped 
patients by whether or not they suffered one of the commonest complications, namely pneumonia, 
atrial fibrillation or anastomotic leak (supplementary table 2). Length of hospital stay in patients who 
suffered an anastomotic leak was significantly increased compared to those without this event (8 days 
vs. 22 days, p=<0.00001), but no other variable was significantly different between groups after 
correction for multiple testing.   
Finally, we undertook univariable logistic regression using variables with a plausible 
association with outcome (age, gender, Charlson comorbidity index, smoking status, BMI, and type of 
operation) and estimated ORs for; any complication, cardiopulmonary and non-cardiopulmonary 
complications in turn. Only age and operation type showed associations (<p=0.10) and were included 
in a multivariable regression model as shown in table 4 (values are from the model excluding CPEX 
variables). The CPEX variables VO2peak and AT were then added individually (due to collinearity) to the 
model to derive their ORs. No associations were found between preoperative CPEX variables and 
morbidity for either VO2peak (OR 1.00, 95% CI 0.94-1.07) or AT (OR 0.98, 95% CI 0.89-1.09) and any type 
of complication. Similar null associations were found for cardiopulmonary and non-cardiopulmonary 
complications.  
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Discussion 
This study investigated the association between preoperative CPEX values and 30-day morbidity in 
206 patients undergoing oesophagectomy. No associations were found between preoperative 
cardiopulmonary fitness, as measured by CPEX testing, and short-term postoperative morbidity.   
This finding is surprising in that it contradicts a seemingly intuitive inverse association. CPEX testing is 
a measure of how efficiently patients are able to deliver oxygen from the environment to cellular 
mitochondria and we would therefore expect patients with large volumes of VO2peak to have a lower 
risk of complications in the early postoperative period, when the demand for oxygen is increased up 
to 1.5 times the normal resting state. 6 However, oesophagectomy is a complex operation which 
delivers a large physiological insult, with complications related to the operative field (anastomotic 
leak, pneumonia and atrial fibrillation). Therefore, the effect of improved aerobic fitness, if present, is 
likely to have a small effect on complications directly related to the surgery. However, 
cardiorespiratory and musculoskeletal reserves may be critical in the ability of a patient to respond 
once a complication has occurred.17 Unfortunately, our study was unable to measure this association 
as mortality was a rare event (n=7).   
Three similar, but smaller, studies to ours have been published to date. 10-12 The largest was a 
Japanese retrospective analysis of 91 patients from a single institution who underwent McKeown 
oesophagectomy for squamous cell carcinoma.10 Only cardiopulmonary complications were measured 
and occurred in 19% of patients. Mean VO2peak (measured in ml/min/m2) was found to be lower in 
those with vs. those without cardiopulmonary complications (789ml/min/m2 vs. 966ml/min/m2, t-test 
p=<0.001). These values approximate to 20.9ml/kg/min vs. 25.6ml/kg/min [our conversion using the 
average height and weight of a Japanese male].18 No association was found between AT and 
complications (t-test, p=0.12). The second largest study was a UK retrospective investigation of 78 
patients, predominantly with adenocarcinoma (74%), undergoing oesophagectomy (64% with 
neoadjuvant chemotherapy).12 Cardiopulmonary outcomes occurred in 42% of patients (n=33) and 
non-cardiopulmonary in 24% (n=19). Similar to the Japanese study, mean VO2peak was associated with 
cardiopulmonary complications although the mean difference was small (19.2ml/kg/min in those with 
complications vs. 21.4ml/kg/min in those without, t-test p=0.04). AT was also similarly not associated 
with complications (13.2ml/kg/min in those with complications vs. 14.4ml/kg/min in those without, t-
test p=0.07). ROC curve analysis estimated the predictive value of both VO2peak and AT to be poor (i.e., 
<70), AUC 0.63 (95% CI 0.50-0.76, p=0.02) and 0.62 (95% CI 0.49-0.75, p=0.03, respectively. Finally, 
there is a retrospective observational study of 103 patients with both oesophageal and gastric cancers 
who underwent CPEX testing prior to oesophagectomy (62%) and gastrectomy.11  This study reported 
that AT was associated with cardiopulmonary complications (9.9ml/kg/min in those with 
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complications vs. 11.2ml/kg/min in those without, p=0.05), while VO2peak was not (16.6ml/kg/min in 
those with complications vs. 14.6ml/kg/min in those without, p=0.07). ROC analysis again found both 
AT and VO2peak to be poorly predictive of complications (AUC 0.62 (95% CI 0.50-0.74, p=0.06) and 0.60 
(95% CI 0.48-0.72, p=0.08, respectively). The most significant limitations of all three studies, apart 
from their small sample sizes and single institution design is the potential for detection bias due to 
unblinded outcome assessment, particularly for complications which can be subjectively diagnosed. 
This would lead to an inflation of the association between CPEX variables and outcomes.  
The strengths of our study include a pre-registered a priori statistical plan, limiting the risk of 
selective reporting bias and type I and II error through sub-analyses. Measurement error was limited 
through the use of a defined diagnostic criteria for complications. We also included blinded outcome 
assessment, which would limit detection bias.  Furthermore, our work is the largest study of its kind, 
with a sufficiently high event rate to detect associations. We undertook a post hoc power calculation 
and estimated that our sample size (n=206) could identify a mean difference in VO2peak, (between 
groups with and without a complication of any cause) of 1.75ml/kg/min and 1.1ml/kg/min for AT, with 
80% power and alpha level at 0.05. We are therefore satisfied that our study had adequate power to 
detect a small difference in CPEX variables between groups if it were present. 
However, there are limitations associated with our methodology. As with all observational 
studies, confounding cannot be excluded. For example, a low VO2peak and AT may not differentiate 
between cardiac disease and poor aerobic fitness.19 However, as the aim was to determine 
associations and not causality between CPEX values and complications (with comorbidity evident by 
poor CPEX scores) it is unlikely that such confounding is relevant here. Performance bias may also have 
occurred due to the clinical team being aware of poor CPEX scores and altering clinical management 
accordingly. This would result in reducing associations between low CPEX scores and morbidity 
towards the null. However, there was no obvious deviation from clinical practice according to CPEX 
results (such as extended HDU stay) in the medical notes, and we consider that such effects on binary 
outcomes are likely to be small. CPEX data was also missing in 16% of the patient population who 
otherwise met the inclusion criteria. However, data was likely to be MCAR and this group was 
comparable to the included group in demography and outcome (supplementary table 1), which 
reduced the risk of selection bias. Finally, our total sample represents a select population of patients 
whom are deemed fit for both neoadjuvant chemotherapy and major surgery. However, this selected 
population had a large distribution of CPEX values (figure 1). We are therefore satisfied that patients 
with ‘low’ scores were included in the analyses, with 35% of patients (n=72) having an AT of 
≤11ml/kg/min. Finally, as death was a rare event, we were unable to examine the associations 
between fitness and mortality.  
 
 
9 
 
Conclusions 
CPEX testing provides an objective measure of fitness in patients undergoing oesophagectomy. 
However, we have shown, that in this specific patient population, aerobic fitness was not associated 
with 30-day morbidity. We postulate that aerobic fitness is likely to have an effect on complication 
rates, as there is a plausible biological mechanism, but the effect size – in the context of the magnitude 
of the surgery  - is likely to be small (explaining why we were unable to measure it in our present 
modestly sized study). The findings from this study, as well as previous work, challenges the utility of 
CPEX testing as a preoperative screening tool prior to oesophagectomy, which is poorly discriminatory 
at best.11 12 This observational work highlights the need for further studies examining associations 
between preoperative CPEX and outcomes after oesophagectomy to look for consistency in our 
findings.  
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Figure Legend 
 
Figure 1. Dot plots showing the distribution of VO2peak (A) and AT (B) for patients with and without 
any complications  
Figure 1 footnote: n=206, 0=absence of a complication, 1=presence of a complication. For VO2peak 
the median value for the whole cohort was 20.8ml/kg/min (range 11.6 to 34.9). For AT the median 
value for the whole cohort was 12.1ml/kg/min (range 7.1 to 22.8)  
 
 
 
 
 
 
References for supplementary table 3 
 
Data was pooled from observational studies examining the association between CPEX testing and post-operative outcome 
in oesophageal,11 12 colorectal,20-22 liver,23 24 bladder 25 26 and lung cancer surgeries.27 The data for healthy volunteers was 
taken from Herdy et al. Reference values for cardiopulmonary exercise testing for sedentary and active men and women. 
Arq Bras Cardiol 2011;96(1):54-9.28 
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Table 1. Patient characteristics 
 
 
 
  
 
 
 
 
  
Variable Study cohort (n=206) 
Number and percentage 
(unless otherwise stated) 
Gender (male) 
 
158 (76.7) 
Age at operation (mean + SD) 
 
66.9 years (9.2) 
Charlson co-morbidity index 
0 
1 
2 
3 or above 
 
 
128 (62.1) 
48 (23.3) 
19 (9.2) 
11 (5.4) 
WHO BMI category (kg/m2) 
Underweight (<18.5) 
Normal weight (18.5-24.9) 
Overweight (25-29.9) 
Class I obesity (30-34.9) 
Class II obesity (35-39.9) 
Class III obesity (≥40) 
 
5 (2.4) 
56 (27.2) 
89 (43.2) 
42 (20.4) 
10 (4.9) 
4 (1.9) 
Smoking status 
Never 
Former 
Current 
Missing 
 
 
65 (31.6) 
120 (58.3) 
12 (5.8) 
9 (4.4) 
T staging (TNM) 
T1 
T2 
T3 
T4 
Unable to be staged  
 
14 (6.8) 
25 (12.1) 
156 (75.7) 
6 (2.9) 
5 (2.4) 
N staging (TNM) 
N0 
N1 
N2 
Unable to be staged  
 
93 (45.1) 
66 (32.1) 
45 (21.8) 
2 (1.0) 
 
Histology 
Adenocarcinoma 
Squamous cell 
Other (leiomyoma, high-grade dysplasia) 
 
 
174 (84.5) 
29 (14.1) 
3 (1.5) 
 
Received neoadjuvant chemotherapy 
 
162 (78.6) 
 
Type of oesophagectomy  
Open McKeown 
Open or partially laparoscopic assisted Ivor Lewis 
Fully laparoscopic (minimally invasive) Ivor Lewis 
 
 
14 (6.8) 
83 (40.3) 
109 (52.9) 
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Table 2. Comparisons between variables of interest according to postoperative complications (any complication, cardiopulmonary and 
non-cardiopulmonary complications). 
Variable Any complication Cardiopulmonary complications Non-cardiopulmonary 
complications 
 Yes (n=111) No (n=95) Yes (n=80) No (n=126) Yes (n=59) No (n=147) 
Gender (male) 82 (74%) 76 (80%) 62 (78%) 96 (76%) 42 (71%) 116 (79%) 
Mean age at operation 
(years + SD) 
 
66.0 (9.4) 
 
67.9 (9.0) 
 
66.2 (10.0) 
 
67.3 (8.7) 
 
65.0 (8.5) 
 
67.6 (9.4) 
Charlson co-morbidity index 
0 
1 
2 
3 or above 
 
73 (65.8) 
22 (19.8) 
10 (9.0) 
6 (5.4) 
 
55 (57.9) 
26 (27.4) 
9 (9.5) 
5 (5.3) 
 
48 (60.0) 
17 (21.3) 
10 (12.5) 
5 (6.3) 
 
80 (63.5) 
31 (24.6) 
9 (7.1) 
6 (4.8) 
 
37 (62.7) 
12 (20.3) 
6 (10.2) 
4 (6.8) 
 
91 (61.9) 
36 (24.5) 
13 (8.8) 
7 (4.8) 
BMI  (mean in kg/m2  + SD) 27.5 (5.7) 27.0 (4.7) 27.5 (5.2) 27.1 (5.3) 27.3 (6.0) 27.3 (4.9) 
Smoking status 
Never 
Former 
Current 
Missing 
 
35 (31.5) 
65 (58.6) 
7 (6.3) 
4 (3.6) 
 
30 (31.6) 
55 (57.9) 
5 (5.3) 
5 (5.3) 
 
25 (31.3) 
45 (56.3) 
7 (8.8) 
3 (3.8) 
 
40 (31.7) 
75 (59.5) 
5 (4.0) 
6 (4.8) 
 
17 (28.8) 
36 (61.0) 
5 (8.5) 
1 (1.7) 
 
48 (32.7) 
84 (57.1) 
7 (4.8) 
8 (5.4) 
T staging 
T1 
T2 
T3 
T4 
Unable to be staged  
 
9 (8.1) 
15 (13.5) 
80 (72.1) 
4 (3.6) 
3 (2.7) 
 
5 (5.3) 
10 (10.5) 
76 (80.0) 
2 (2.1) 
2 (2.1) 
 
7 (8.8) 
14 (17.5) 
52 (65.0) 
4 (5.0) 
3 (3.8) 
 
7 (5.6) 
11 (8.7) 
104 (82.5) 
2 (1.6) 
2 (1.6) 
 
6 (10.2) 
7 (11.9) 
43 (72.9) 
1 (1.7) 
2 (3.4) 
 
8 (5.4) 
18 (12.2) 
113 (76.9) 
5 (3.4) 
3 (2.0) 
N staging 
N0 
N1 
N2 
Unable to be staged  
 
53 (47.7) 
35 (31.5) 
22 (19.8) 
1 (0.9) 
 
40 (42.1) 
31 (32.6) 
23 (24.2) 
1 (1.1) 
 
40 (50) 
23 (28.8) 
16 (20.0) 
1 (1.3) 
 
53 (42.1) 
43 (34.1) 
29 (23.0) 
1 (0.8) 
 
31(52.5) 
18 (30.5) 
10 (16.9) 
0 
 
62 (42.2) 
48 (32.7) 
35 (23.8) 
2 (1.4) 
Histology 
Adenocarcinoma 
Squamous cell 
Other (leiomyoma, HGD) 
 
91 (82.0) 
18 (16.2) 
2 (1.8) 
 
83 (87.4) 
11 (11.6) 
1 (1.1) 
 
64 (80.0) 
14 (17.5) 
2 (2.5) 
 
110 (87.3) 
15 (11.9) 
1 (0.8) 
 
51 (86.4) 
8 (13.6) 
0  
 
123 (83.7) 
21 (14.3) 
3 (2.0) 
Received neoadjuvant 
chemotherapy 
 
85 (76.6) 
 
77 (81.1) 
 
59 (73.8) 
 
103 (81.7) 
 
46 (78.0) 
 
116 (78.9) 
Type of oesophagectomy  
Open McKeown 
Open or partially laparoscopic 
assisted Ivor Lewis 
Fully laparoscopic (minimally 
invasive) Ivor Lewis 
 
10 (9.0) 
 
48 (43.2) 
 
53 (47.7) 
 
4 (4.2) 
 
35 (36.8) 
 
56 (58.9) 
 
5 (6.3) 
 
32 (40.0) 
 
43 (53.8) 
 
9 (7.1) 
 
51 (40.5) 
 
66 (52.4) 
 
8 (13.6) 
 
32 (54.2) 
 
19 (32.2) 
 
6 (4.1)d 
 
51 (34.7)c 
 
90 (61.2)b 
Duration of surgery in mins 
(median, 25th- 75th percentile) 
 
464 (365-542) 
 
455 (381-525) 
 
478 (391-556) 
 
443 (369-519)f 
 
424 (334-509) 
 
465 (385-541)e 
Length of stay in days  
(median, 25th-75th percentile) 
 
12 (8 – 20) 
 
7 (6-9)a 
 
11.5 (8-18.5) 
 
8 (6-11)a 
 
17 (12-29) 
 
8 (7-10)a 
 
For categorical variable, X2 tests were used, but only when total cell counts were >50, otherwise Fisher’s exact tests were applied. For continuous variables with a 
normal distribution, Students-t tests were used, where distribution was non-normal, Mann-Whitney U tests were used. All percentages represent the proportion 
of patients with or without a complications (yes/no). P-values reaching conventional statistical significance (p=0.05) are shown in superscript. Bonferroni adjusted 
significance is p=0.0008, in which case the superscript is shown in bold. aP=<0.00001, bP=0.001, cP=0.01, dP=0.02, eP=0.04, fP=0.05. 
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Table 3. Comparisons between mean cardiopulmonary exercise testing variables according to post-operative complication 
outcomes (type and severity).  
CPEX variable Type of complication P-value 
 Any complications (n=111) No complications (n=95)  
VO2peak (ml/kg/min) 21.3 (4.7) 20.9 (4.2) 0.54 
AT (ml/kg/min) 12.4 (2.9) 12.4 (2.8) 0.95 
 Any complications of C-D grade 3 (n=39) No complications (n=95)  
VO2peak (ml/kg/min) 20.4 (4.4) 20.9 (4.2) 0.52 
AT (ml/kg/min) 12.2 (3.1) 12.4 (2.8) 0.73 
 Any complications of C-D grade 4 (n=16) No complications (n=95)  
VO2peak (ml/kg/min) 21.0 (3.3) 20.9 (4.2) 0.94 
AT (ml/kg/min) 13.0 (3.1) 12.4 (2.8) 0.42 
 Cardiopulmonary complications (n=80) No cardiopulmonary complications (n=126)  
VO2peak (ml/kg/min) 21.7 (5.0) 20.8 (4.1) 0.14 
AT (ml/kg/min) 12.5 (2.9) 12.3 (2.8) 0.59 
 Non-cardiopulmonary complications (n=59) No non-cardiopulmonary complications (n=143)  
VO2peak (ml/kg/min) 20.8 (4.1) 21.2 (4.6) 0.56 
AT (ml/kg/min) 12.4 (2.9) 12.3 (2.8) 0.91 
C-D= Clavien-Dindo severity classification. All P-values obtained using Student-t tests.  
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Table 4. Multivariable logistic regression modelling 
CPEX variable Any complication 
Odds ratio , 95% CI and P-value 
Cardiopulmonary complications 
Odds ratio , 95% CI and P-value 
Non-cardiopulmonary complications 
Odds ratio , 95% CI and P-value 
 
VO2peak (ml/kg/min) 
 
 
1.00 (0.94-1.07), p=0.862 
 
 
1.04 (0.98-1.12), p=0.204 
 
0.98 (0.88-1.03), p=0.191 
 
AT (ml/kg/min) 0.98 (0.89-1.09), p=0.769 1.02 (0.92-1.13), p=0.675 0.98 (0.88-1.11), p=0.792 
The ORs are for the individual CPEX variables and risk of complications after adjustment for age and type of operation by category 
(minimally invasive, open or hybrid Ivor Lewis, McKeown oesophagectomy).  
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Figure 2. Dot plots showing the distribution of VO2peak (A) and AT (B) for patients with and without any complications  
 
   A              B 
n=206, 0=absence of a complication, 1=presence of a complication. For VO2peak the median value for the whole cohort was 
20.8ml/kg/min (range 11.6 to 34.9). For AT the median value for the whole cohort was 12.1ml/kg/min (range 7.1 to 22.8)  
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Supplementary Table 1. Comparison of cohorts with and without CPEX data (by any complication) 
Variable Any complication of included cohort 
(n=206) 
Any complication of excluded cohort 
(n=40) 
 Yes (n=111) No (n=95) Yes (n=19) No (n=21) 
Gender (male) 82 (74%) 76 (80%) 13 (68.4) 17 (81.0) 
Mean age at operation 
(years + SD) 
 
66.0 (9.4) 
 
67.9 (9.0) 
 
66.7 (9.8) 
 
63.8 (9.1) 
Charlson co-morbidity index 
0 
1 
2 
3 or above 
 
73 (65.8) 
22 (19.8) 
10 (9.0) 
6 (5.4) 
 
55 (57.9) 
26 (27.4) 
9 (9.5) 
5 (5.3) 
 
15 (78.9) 
4 (21.1) 
0 
0 
 
16 (76.2) 
4 (19.0) 
1 (4.8) 
0 
Smoking status 
Never 
Former 
Current 
Missing 
 
35 (31.5) 
65 (58.6) 
7 (6.3) 
4 (3.6) 
 
30 (31.6) 
55 (57.9) 
5 (5.3) 
5 (5.3) 
 
4 (21.1) 
10 (52.6) 
4 (21.1) 
1 (5.3) 
 
9 (42.9) 
11 (52.4) 
0 
1 (4.8) 
T staging 
T1 
T2 
T3 
T4 
Unable to be staged  
 
9 (8.1) 
15 (13.5) 
80 (72.1) 
4 (3.6) 
3 (2.7) 
 
5 (5.3) 
10 (10.5) 
76 (80.0) 
2 (2.1) 
2 (2.1) 
 
3 (15.8) 
3 (15.8) 
13 (68.4) 
0 
0 
 
2 (9.5) 
3 (14.3) 
16 (76.2) 
0 
0 
N staging 
N0 
N1 
N2 
Unable to be staged  
 
53 (47.7) 
35 (31.5) 
22 (19.8) 
1 (0.9) 
 
40 (42.1) 
31 (32.6) 
23 (24.2) 
1 (1.1) 
 
8 (42.1) 
5 (26.3 
5 (26.3) 
1 (5.3) 
 
13 (61.9) 
6 (28.6) 
2 (9.5) 
0 
Histology 
Adenocarcinoma 
Squamous cell 
Other (leiomyoma, HGD) 
 
91 (82.0) 
18 (16.2) 
2 (1.8) 
 
83 (87.4) 
11 (11.6) 
1 (1.1) 
 
14 (73.7) 
5 (26.3) 
0 
 
18 (85.7) 
3 (14.3) 
0 
Received neoadjuvant 
chemotherapy 
 
85 (76.6) 
 
77 (81.1) 
 
15 (78.9) 
 
18 (85.7) 
Type of oesophagectomy  
Open McKeown 
Open or partially laparoscopic 
assisted Ivor Lewis 
Fully laparoscopic (minimally 
invasive) Ivor Lewis 
 
10 (9.0) 
 
48 (43.2) 
 
53 (47.7) 
 
4 (4.2) 
 
35 (36.8) 
 
56 (58.9) 
 
3 (15.8) 
 
8 (42.1) 
 
8 (42.1) 
 
1 (4.8) 
 
12 (57.1) 
 
8 (38.1) 
Length of stay in days  
(median, 25th-75th percentile) 
 
12 (8 – 20) 
 
7 (6-9)  
 
11 (10-22) 
 
7 (6-7) 
Duration of surgery in mins 
(median, 25th- 75th percentile) 
 
464 (365-542) 
 
455 (381-525) 
 
421 (337-519) 
 
416 (345-480) 
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Supplementary table 2. Comparisons between variables of interest according to common post-operative complications. 
For categorical variable, X2 tests were used, but only when total cell counts were >50, otherwise Fisher’s exact tests were applied. For continuous variables 
with a normal distribution, Students-t tests were used, where distribution was non-normal, Mann-Whitney U tests were used. All percentages represent the 
proportion of patients with or without a complications (yes/no). P-values reaching conventional statistical significance (p=0.05) are shown in superscript. 
Bonferroni adjusted significance is p=0.0008, in which case the superscript is shown in bold. aP=<0.00001, bP=0.0008, cP=0.007, dP=0.01, eP=0.02, fP=0.04. 
 
 
 
 
 
 
 
Variable Pneumonia 
 
Atrial fibrillation Anastomotic leak 
 Yes (n=42) No (n=164) Yes (n=36) No (n=170) Yes (n=39) No (n=167) 
Gender (male) 35 (83.3) 123 (75.0) 26 (72.2) 132 (77.6) 31 (79.5) 127 (76.0) 
Mean age at operation 
(years + SD) 
68.1 (9.1) 66.6 (9.3) 68.3 (8.9) 66.6 (9.3) 64.1 (8.5) 67.5 (9.3)f 
COPD diagnosis 8 (19.0) 18 (11.0) 9 (25.0) d 17 (10.0)  8 (20.5) 18 (10.8) 
Previous MI 6 (14.3) 12 (7.3) 3 (8.3) 15 (8.8) 5 (12.8) 13 (7.8) 
BMI  
(mean in kg/m2  + SD) 
27.7 (5.2) 27.2 (5.2) 27.6 (5.2) 27.2 (5.3) 28.0 (6.6) 27.1 (4.9) 
Smoking status 
Never 
Former 
Current 
Missing 
 
14 (33.3) 
23 (54.8) 
3 (7.1) 
2 (4.8) 
 
51 (31.1) 
97 (59.1) 
9 (5.5) 
7 (4.3) 
 
11 (30.6) 
24 (66.7) 
1 (2.8) 
0 
 
54 (31.8) 
96 (56.5) 
11 (6.5) 
9 (5.3) 
 
9 (23.1) 
24 (61.5) 
4 (10.3) 
2 (5.1) 
 
56 (33.5) 
96 (57.5) 
8 (4.8) 
7 (4.2) 
Had neoadjuvant 
chemotherapy 
 
27 (64.3) 
 
135 (82.3) d 
 
29 (80.6) 
 
133 (78.2) 
 
32 (82.1) 
 
130 (77.8) 
Type of oesophagectomy  
Open McKeown 
Open or partially 
laparoscopic assisted Ivor 
Lewis 
Fully laparoscopic 
(minimally invasive) Ivor 
Lewis 
 
 
2 (4.8) 
 
19 (45.2) 
 
 
21 (50) 
 
 
12 (7.3) 
 
64 (39.0) 
 
 
88 (53.7) 
 
 
2 (5.6) 
 
11 (30.6) 
 
 
23 (63.9) 
 
 
12 (7.1) 
 
72 (42.4) 
 
 
86 (50.6) 
 
 
6 (15.4) 
 
20 (51.3) 
 
 
13 (33.3) 
 
 
8 (4.8)e 
 
63 (37.7) 
 
 
96 (57.5)c 
Duration of surgery 
(mins) 
 
475 (344-545) 
 
455 (370-526) 
 
489 (427-556) 
 
451 (365-526) f 
 
406 (334-490) 
 
462 (381-536) f 
Length of stay in days  
(median, 25th to 75th 
percentile) 
 
 
10 (8-15) 
 
 
8.5 (7-13) 
 
 
13 (8-19.5) 
 
 
8 (7-12) b 
 
 
22 (15-35) 
 
 
8 (7-10) a 
CPEX (mean + SD) 
VO2peak (ml/kg/min) 
AT (ml/kg/min) 
 
20.8 (5.0) 
12.0 (2.6) 
 
21.2 (4.3) 
12.5 (2.9) 
 
21.2 (5.2) 
12.5 (3.2) 
 
21.1 (4.3) 
12.3 (2.8) 
 
20.7 (3.7) 
12.7 (2.9) 
 
21.2 (4.6) 
12.3 (2.8) 
